Last mentioned: Feb 26, 2026
A wave of Q4 2025 earnings reports from mid-cap leaders across healthcare, automotive, and retail sectors highlights a bifurcated recovery. While MedTech and high-end retail show margin expansion, the EV and industrial sectors continue to navigate significant production and scaling headwinds.
Axon Enterprise is set to report Q4 2025 results, with investors focused on the adoption of AI-driven tools like Draft One and the continued rollout of TASER 10. Meanwhile, specialty pharma players Corcept and Supernus prepare to disclose their own year-end performance amid shifting regulatory and competitive landscapes.
This page surfaces every story mentioning Supernus Pharmaceuticals across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Supernus Pharmaceuticals was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |